Evidence map›Paper›PMID 39465249›Full record

ArticleNPJ vaccines2024

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

Alberto Moreno, Kelly Manning, Maryam I Azeem, Ajay K Nooka, Madison Ellis, Renee Julia Manalo, Jeffrey M Switchenko, Bushra Wali, Jonathan L Kaufman, Craig C Hofmeister and 5 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Alberto MorenoEmory Vaccine Center, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0002-3031-7194
Kelly ManningEmory Vaccine Center, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0002-6262-1190
Maryam I AzeemDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Ajay K NookaDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Madison EllisEmory Vaccine Center, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0002-0325-5477
Renee Julia ManaloDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Jeffrey M SwitchenkoWinship Cancer Institute, Atlanta, Georgia.
Bushra WaliEmory Vaccine Center, Emory University, Atlanta, Georgia.
Jonathan L KaufmanDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Craig C HofmeisterDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0003-4816-1607
Nisha S JosephDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Sagar LonialDepartment of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Kavita M DhodapkarAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0003-0587-4172
Madhav V Dhodapkar *Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia. madhav.v.dhodapkar@emory.edu.ORCID http://orcid.org/0000-0002-8249-5988
Mehul S Suthar *Emory Vaccine Center, Emory University, Atlanta, Georgia. msuthar@emory.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3M
Project-004U54CA260563 · NCI · EMORY UNIVERSITY · PI DHODAPKAR, MADHAV V, SANZ, IGNACIO E. · 2020 to 2024
$10.2M
HARNESSING HOST RESPONSE TO PREVENT MYELOMAR35CA197603 · NCI · YALE UNIVERSITY · PI DHODAPKAR, MADHAV V · 2016 to 2022
$5.8M
B cells in autoimmunity following checkpoint blockade therapyR01CA238471 · NCI · EMORY UNIVERSITY · PI DHODAPKAR, KAVITA MADHAV, SANZ, IGNACIO E. · 2019 to 2023
$2.3M
B cell depletion to prevent autoimmunityR01AR077926 · NIAMS · EMORY UNIVERSITY · PI DHODAPKAR, KAVITA MADHAV, SANZ, IGNACIO E. · 2020 to 2023
$1.6M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA238471NCI NIH HHS R35 CA197603NCI NIH HHS U54 CA260563NIAID NIH HHS 75N93021C00017NIAID NIH HHS HHSN272201400004CNIAID NIH HHS U19 AI057266NIAMS NIH HHS R01 AR077926NIH HHS P51 OD011132
6 · The paper itself

Abstract

Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Identifiers

PMID39465249
PMCPMC11514147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.